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In the performance of infrainguinal revascular-
ization procedures, the greater saphenous vein
(GSV) has achieved unequaled long-term patency
and limb-salvage rates.1-7 Consequently, the ipsilat-
eral GSV is regarded as the conduit of choice for
lower-extremity revascularization.8-11 However, a
significant proportion of patients who have critical
lower-extremity ischemia do not possess a usable
ipsilateral GSV. The incidence of absence of an ade-
quate ipsilateral GSV has been reported to be as high
as 40% to 45%.1,12,13 This poses a difficult clinical
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Purpose: The absence of an adequate ipsilateral saphenous vein in patients requiring
lower-extremity revascularization poses a difficult clinical dilemma. This study examined
the results of the use of autogenous arm vein bypass grafts in these patients.
Methods: Five hundred twenty lower-extremity revascularization procedures performed
between 1990 and 1998 were followed prospectively with a computerized vascular reg-
istry. The arm vein conduit was prepared by using intraoperative angioscopy for valve
lysis and identification of luminal abnormalities in 44.8% of cases.
Results: Seventy-two (13.8%) femoropopliteal, 174 (33.5%) femorotibial, 29 (5.6%)
femoropedal, 101 (19.4%) popliteo-tibial/pedal, and 144 (27.7%) extension “jump”
graft bypass procedures were performed for limb salvage (98.2%) or disabling claudica-
tion (1.8%). The average age of patients was 68.5 years (range, 32 to 91 years); 63.1%
of patients were men, and 36.9% of patients were women. Eighty-five percent of patients
had diabetes mellitus, and 77% of patients had a recent history of smoking. The grafts
were composed of a single arm vein segment in 363 cases (69.8%) and of spliced com-
posite vein with venovenostomy in 157 cases (30.2%). The mean follow-up period was
24.9 months (range, 1 month to 7.4 years). Overall patency and limb salvage rates for
all graft types were: primary patency, 30-day = 97.0% ± 0.7%, 1-year = 80.2% ± 2.1%, 3-
year = 68.9% ± 3.6%, 5-year = 54.5% ± 6.6%; secondary patency, 30-day = 97.0% ± 0.7%,
1-year = 80.7% ± 2.1%, 3-year = 70.3% ± 3.4%, 5-year = 57.5% ± 6.2%; limb salvage, 30-
day = 97.6% ± 0.7%, 1-year = 89.8% ± 1.7%, 3-year = 82.1% ± 3.3%, 5-year = 71.5% ±
6.9%. Secondary patency and limb salvage rates were greatest at 5 years for
femoropopliteal grafts (69.8% ± 12.8%, 80.7% ± 11.8%), as compared with femorotibial
(59.6% ± 10.3%, 72.7% ± 10.5%), femoropedal (54.9% ± 25.7%, 56.8% ± 26.9%,) and
popliteo-tibial/pedal grafts (39.0% ± 7.3%, 47.6% ± 15.4%). The patency rate of com-
posite vein grafts was equal to that of single-vein conduits. The overall survival rate was
54% at 4 years.
Conclusion: Autogenous arm vein has been used successfully in a wide variety of lower-
extremity revascularization procedures and has achieved excellent long- and short-term
patency and limb salvage rates, higher than those generally reported for prosthetic or
cryopreserved grafts. Its durability and easy accessibility make it an alternative conduit of
choice when an adequate saphenous vein is not available. (J Vasc Surg 2000;31:50-9.)
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dilemma and has given rise to the question of which
alternative conduit should be used for lower-extrem-
ity revascularization in the absence of an adequate
ipsilateral GSV.14 The alternatives include autoge-
nous conduits such as basilic and cephalic arm veins,
lesser saphenous vein (LSV), remnant GSV, deep leg
veins, inferior epigastric artery, and the contralateral
GSV.15-22 The use of prosthetic grafts, including
polytetrafluoroethylene and Dacron, with or with-
out adjunctive measures such as vein cuffs and arte-
riovenous fistulas (AVFs), has been undertaken.23-27
Other nonautogenous alternative conduits that have
been used include gluteraldehyde-stabilized umbili-
cal vein, cryopreserved saphenous vein allografts,
and composite prosthetic-autogenous conduits.28-31
Nonautogenous conduits have achieved reason-
able success when the popliteal artery has been the
outflow target vessel and have provided a better
alternative than primary amputation when anasto-
mosed to tibial arteries in several series, including
multicenter trials.8,32 At our institution, we have
pursued a policy of using arm veins as the first alter-
native conduit for lower-extremity revascularization
when the ipsilateral saphenous vein is not available.
This report describes the results of this policy in 520
procedures performed in an 8-year period.
PATIENTS AND METHODS
Patient demographics. From Jan 1, 1990, to
Aug 31, 1998, a consecutive series of 3019 infrain-
guinal arterial reconstructions was performed. Of
these, 520 revascularization procedures were per-
formed in 454 patients with arm vein conduit exclu-
sively. The demographics of the 520 patients who
received arm vein revascularization are shown in Table
I. The indication for use of an arm vein conduit was
the absence of an adequate ipsilateral GSV. The rea-
sons for absence of the GSV are listed in Table II.
Most of the arm vein revascularization procedures
(512, 98.2%) were performed for limb salvage, includ-
ing gangrene in 123 cases (23.7%), ischemic ulcer in
303 cases (58.6%), and ischemic rest pain in 85 cases
(16%). Only nine arm vein revascularizations (1.8%)
were performed for disabling claudication. Arm vein
was used for the initial procedure in 246 cases and for
revision procedures in 274 cases. The definitions and
classification of all criteria used were those recom-
mended by the Ad Hoc Committee on Reporting
Standards of The Society for Vascular Surgery/North
American Chapter of the International Society for
Cardiovascular Surgery.33
Vein graft preparation. Arm veins were har-
vested by using continuous upper-extremity inci-
sions. The arm vein was maintained in a distended
state in cooled, balanced salt solution to preserve
intimal and medial integrity, as described in a previ-
ous report.34 The method of arm vein harvest and
preparation has been described in detail in previous
publications.13 Angioscopic evaluation was per-
formed during 44.8% of procedures as a means of
assessing the luminal characteristics.35 Angioscopes
ranged in size from 0.8 to 2.2 mm in outer diameter
(Olympus, Lake Success, NY). Luminal abnormali-
ties were corrected either by using angioscopic guid-
ance (removal of adherent thrombus, lysis of endolu-
minal strands) or externally (vein patch angioplasty).
Alternatively, resection of the abnormal segments was
performed when repair was not possible (vein sclero-
sis). Valve lysis of nonreversed vein segments was also
performed with angioscopic guidance or with direct
visualization for short vein segments.
The bypass grafts were composed of a single arm
vein segment in 363 cases (69.8%) and a spliced com-
posite vein with venovenostomy in 157 cases (30.2%).
Venovenostomies were performed end-to-end with 7-
0 prolene suture (Ethicon, Sommerville, NJ) to cre-
ate a vein conduit of sufficient length and quality to
allow the performance of the lower-extremity revas-
cularization. The specific arterial reconstructive pro-
cedures performed are listed in Table III.




Recent history of smoking 77
Average age 68.5 years
Coronary artery disease 65.7
Previous CABG or PTCA 42.6
Hypertension 66.3
End-stage renal disease 14.7
CABG, Coronary artery bypass graft; PTCA, percutaneous trans-
luminal coronary angioplasty.
Table II. Factors determining the use of arm vein
conduit
Indication Percentage
Earlier ipsilateral revascularization 61.3
Earlier coronary revascularization 22.5
Ipsilateral vein inadequate 9.1
Earlier vein stripping 5.2
Earlier ipsilateral and coronary bypass graft 1.5
Earlier contralateral revascularization 0.4
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Postoperative follow-up. Patients were observed
with office visits every 3 months during the first year
and every 6 months thereafter. Graft patency was
determined by means of continuous-wave Doppler
examination and by clinical examination of pulses dis-
tal to the bypass graft. Selective color-flow duplex
examination was also performed as a means of deter-
mining graft patency or defining flow abnormalities in
28% of cases. The criteria for patency and the defini-
tions of primary, assisted-primary, and secondary
patency, limb-salvage, and survival rates used in this
study are those outlined by the Ad Hoc Committee on
Reporting Standards of The Society for Vascular
Surgery/North American Chapter of the Inter-
national Society for Cardiovascular Surgery.33 The fol-
low-up period ranged from 1 month to 7.4 years, with
an average follow-up period of 24.9 months.
Database and statistical analysis. All vascular
procedures performed at the Beth Israel Deaconess
Medical Center since Jan 1, 1990, have been entered
prospectively in a vascular registry. This computer-
ized vascular surgery database was used to collect all
data regarding each patient, procedure, and follow-
up. Life table analysis was used as a means of calcu-
lating patency, limb-salvage, and survival rates.
Comparison between life table curves was performed
by using the Mantel-Cox log-rank test for signifi-
cance. Figures are represented as the mean plus or
minus standard error. Other continuous variables
were compared with a Student t test, and discrete
parameters were compared by using chi-square analy-
sis. Significance was assumed at P values less than .05.
RESULTS
Morbidity and mortality. The overall periop-
erative morbidity rate was 6.9%. Complications
included myocardial infarction (1%), pulmonary fail-
ure requiring intubation (0.4%), renal failure requir-
ing dialysis (1%), hematoma (2.3%), wound infec-
tion (1.9%), and graft thrombosis (2.9%; Table IV).
A return to the operating room was required in 15
patients (2.9%). The 30-day mortality rate was 1.2%.
This was not significantly different from the rate for
all lower-extremity revascularization procedures at
our institution during the same period. Morbidity
resulting from arm vein harvest occurred in six
patients (1.2%). This included four patients who
experienced numbness over the volar aspect of the
forearm and two patients in whom self-limited
upper-extremity edema developed. The edema
caused discomfort, but no further sequelae, and
required no intervention.
Graft patency, limb salvage, and survival.
The overall primary, assisted-primary, and secondary
patency rates and limb-salvage rates for all arm vein
conduit infrainguinal arterial reconstructions are
shown in Fig 1. The 30-day rates exceeded 97% for
all patency and for limb salvage. The 5-year rates
were: primary, 54.5% ± 6.6%; secondary, 57.5% ±
6.2%; limb-salvage, 71.5% ± 6.9%. Patency and limb-
salvage rates varied, depending on graft configura-
tion and inflow source (Fig 2), with significantly
greater patency rates for grafts originating from the
femoral artery than for those originating from the
popliteal artery (5-year secondary patency, 59.6% ±
8.1% vs 39.0% ± 13.6%, P < .01; 5-year limb salvage,
75.2% ± 8.0% vs 47.6% ± 15.4%, P < .01). Secondary
patency and limb-salvage rates were greatest at 5
years for femoropopliteal grafts (69.8% ± 12.8%,
80.7% ± 11.8%), as compared with femorotibial
(59.6% ± 10.3%, 72.7% ± 10.5%), femoropedal
(54.9% ± 25.7%, 56.8% ± 26.9%), and popliteo-tib-
ial/pedal grafts (39.0% ± 7.3%, 47.6% ± 15.4%).
Interposition “jump” grafts had 4-year cumulative
patency and limb-salvage rates of 54.3% ± 10.2% and
72.8% ± 11.7%, respectively. The overall survival rate
was 54% at 4 years and is depicted in Fig 3.
Arm vein bypass grafts performed as the initial
revascularization procedure (N = 246) demonstrat-
ed an increased trend in primary and secondary
patency and limb-salvage rates, compared with arm
vein conduits used for revision or “redo” revascu-
larization procedures (N = 274). These trends
approached statistical significance at the 4-year
point (primary patency, initial procedure = 67.6% ±
8.6% vs revision = 56.8% ± 6.3%, P = .08; sec-
ondary patency, initial procedure = 69.8% ± 8.0% vs
59.3% ± 5.8%, P = .09; Fig 4). Minimal difference
in rates of primary and secondary patency and limb
Table III. Anatomic configuration of revascular-
ization procedure
Number of 
Graft configuration Outflow vessel grafts
Femoropopliteal Popliteal–above knee 29
Popliteal–below knee 43
Femorotibial Anterior tibial 69
Posterior tibial 52
Peroneal 53





Extension “jump” Proximal 44
Distal 85
Interposition 15
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salvage was observed between single-segment arm
vein bypass grafts and spliced, multisegment arm
vein grafts (Fig 5).
Contralateral greater saphenous vein. The
fate of the available contralateral GSV was followed
in 107 patients. The average follow-up period for
these patients was 14.8 months. During this period,
23% of the contralateral GSVs were used for either
contralateral infrainguinal (97%) or coronary (3%)
revascularization. The probability of using the con-
tralateral GSV was 15% ± 4.5% at 1 year and 26.4%
± 7.1% at 2 years.
Fig 2. Life table analysis of secondary patency rates categorized by inflow source vessel. Grafts
with the femoral artery as the inflow source demonstrate significantly improved patency, as
compared with those with popliteal inflow (P < .01). Life table analysis of limb salvage cate-
gorized by means of inflow vessel also showed grafts originating from the femoral artery are
superior to those from the popliteal artery (P < .01).
Fig 1. Life table analysis of the overall rates of primary, secondary, and limb salvage rates for
all arm vein bypass grafts.
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DISCUSSION
Direct revascularization of the ischemic lower-
extremity has undergone dramatic change since the
initial reports of Dos Santos and Kunlin.36,37 The
continuing evolution and refinement of vascular sur-
gical techniques have produced significant improve-
ment in limb preservation and a decreased incidence
of lower-extremity amputation.38 Abundant data
attest to the effectiveness of infrainguinal revascular-
ization in producing superior long-term patency and
limb-salvage rates in the last 3 decades.1-9 However,
the need for alternative conduits for lower-extremity
revascularization has become increasingly evident, as
the practice of infrainguinal reconstruction has
Fig 3. Life table analysis of survival after arm vein revascularization.
Fig 4. Life table analysis of primary patency as a function of procedure type: primary versus
revision. Primary revascularization procedures show a trend toward increased primary patency
that approaches statistical significance at the 4-year point (P = .08). Life table analysis of limb
salvage as a function of procedure type also showed a trend toward superior results for prima-
ry revascularization procedures that did not attain statistical significance.
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become more widespread and multiple procedures
are performed to salvage a single extremity.
The first use of arm vein as an alternative conduit
for lower-extremity revascularization was reported 
in 1969.39 Additional reports that soon followed
demonstrated the feasibility of arm vein bypass grafts,
but were limited by the small numbers of patients
and short follow-up periods.40,41 Some early descrip-
tions raised concern because of relatively poor long-
term patency rates.42 However, definitive reports by
Andros, Campbell, and others confirmed the poten-
tial for achieving long-term patency and limb salvage
using arm vein conduit.19,43 More recent reports
involving more patients have provided further evi-
dence supporting the use of arm vein conduits. In
these modern reports, 3-year cumulative patency
rates ranged from 46% to 73%, and 3-year limb-sal-
vage rates ranged from 63% to 85%.13,18,20,45,46
At our medical center, we use arm vein as the
first alternative conduit when the ipsilateral GSV is
absent or inadequate for bypass grafting. The GSV is
considered inadequate when it contains significant
vericosities or when it is less than 10 cm long.
Preference for arm vein conduit is based on several
factors. First is the need to establish a minimally
thrombogenic conduit of adequate length and cal-
iber to approach the patency rate of GSV. Arm vein
is easily accessible and is relatively technically simple
to harvest. Generally adequate lengths of sufficient
caliber can obtained, particularly when end-to-end
splicing techniques are used to create venovenos-
tomies. Preoperative vein mapping is used frequent-
ly in these patients as a means of identifying suitable
arm vein segments.
Arm vein harvest results in minimal morbidity, less
than 2% in this study. Some authors have expressed
concern about the fragility of arm vein conduit,14 and
one report advocates arterialization of the arm veins
before their use as a bypass grafting conduit, report-
ing results in five patients.46 However, most authors
report success in handling arm veins, without signifi-
cant difficulties in tearing, stenosing, or perforating
the vein.13,16-18,20,44,45 In addition, arm vein may
provide some advantage for compliance match with
the target artery and ease of performance of the distal
anastomosis, particularly when compared with the
direct anastomosis of prosthetic grafts to small caliber,
Fig 5. Life table analysis of cumulative secondary patency for single versus multiple arm vein
segments. Primary and secondary patency was markedly similar between single and multiple vein
segments (P = NS). Limb salvage also did not differ significantly between these groups (P = NS).
Table IV. Morbidity and mortality
Local complications Type Number (%)
Hematoma 12 (2.3%)
Wound infection 10 (1.9%)
Wound dehiscence 1 (0.2%)
Hemorrhage 3 (0.6%)
Graft infection 2 (0.4%)
Systemic complications
Myocardial infarction 5 (1%)
Renal failure (dialysis) 5 (1%)
Pulmonary failure (intubation) 2 (0.4%)
Pneumonia 5 (1%)
30-day mortality 6 (1.2%)
calcified tibial or pedal arteries. Additional potential
advantages over prosthetic grafts include a possible
decrease in susceptibility to infection47 and no
requirement for adjunctive measures, notably AVFs,
which have been associated with a distal steal phe-
nomenon.25,48
Long-term patency and limb-salvage rates that
approach those reported here by using prosthetic con-
duits with adjunctive measures such as a vein cuff or an
AVF have been reported by some authors.24,26,27
However, in most reports and in multicenter trials,
other investigators have not been successful in match-
ing these success rates.8,9,32,49,50 Successful use of
prosthetic grafts may only be possible in the hands of
vascular surgeons who have extensive experience with
these grafts.
Analysis of the subgroups in this report demon-
strates inferior results when the popliteal artery is
used for inflow (5-year secondary patency, 38.2% ±
7.3%). The limb-salvage rate at 5 years was accept-
able at 47.6% ± 15.4%, particularly in comparison
with other alternative conduits or primary amputa-
tion. However, the 5-year limb-salvage rate in the
present study did not match the rates reported for
GSV grafts originating from the popliteal artery.51,52
The reduced patency rates for these grafts occurred
late in the follow-up period and most frequently
resulted from progression of atherosclerotic disease
in the native arteries. In bypass grafts that use the
popliteal artery for inflow, consideration should be
given to the use of the contralateral GSV, particular-
ly when it can be harvested without extending the
incision below the calf level.
Alternatively, some authors advocate the use of
the LSV and remnants of the GSV.12,15-17 By using
these alternative autogenous vein conduits, the
authors achieve high long-term patency and limb-
salvage rates. And, although harvest of the LSV may
require placement of the patient in the prone posi-
tion with subsequent repositioning to the supine
position for performance of the bypass grafting pro-
cedure, use of the LSV for lower-extremity revascu-
larization without repositioning has been reported.
Thus, use of the LSV and GSV remnant provides a
favorable alternative when the ipsilateral GSV is not
of sufficient length or quality.
The use of the contralateral GSV has also been
advocated. Several factors detract from the appeal of
the contralateral GSV in certain patient populations.
The need for revascularization of the contralateral
limb is a leading reason. This need has been report-
ed to be 20% to 23%.13,53 The relative risk of requir-
ing contralateral lower-extremity revascularization is
increased by the presence of diabetes mellitus, coro-
nary artery disease, age older than 70 years, and an
initial ankle-brachial index less than 0.7.54 These
characteristics are common in patients with critical
lower-extremity ischemia at our institution. As a
result, we favor preserving the contralateral GSV. In
addition, because lower-extremity ischemia typically
occurs with a significant degree of bilaterality, the
possibility of impaired healing of the contralateral
GSV harvest site is of concern, particularly in the
infrageniculate region. These factors not withstand-
ing, several authors favor the contralateral GSV as a
preferred alternative when the ipsilateral GSV is
unsuitable for use as an arterial conduit. They cite
excellent patency and limb-salvage rates, technical
ease, and the avoidance of vein splicing.1,12
The observation that most arm vein bypass graft-
ing procedures in the present study were performed
as revisions or “redo” procedures was not unexpect-
ed. In most patients, the absence of a suitable ipsi-
lateral GSV was attributable to its use for a previous
revascularization procedure performed on that limb.
This may highlight the value of preserving the GSV
when possible.
The primary and secondary patency and limb-sal-
vage rates of single vein grafts was remarkably similar
to that of multiple segment grafts. One possible
interpretation of these results is that the site of veno-
venostomy is not significantly prone to stenosis and
graft failure. This idea is supported by the finding
that venovenostomy is an uncommon site of graft
failure in this study. Therefore, the need for multiple
vein segments and venovenostomies should not dis-
courage the use of these shorter vein segments.
In conclusion, although several alternative con-
duit options are available for use when an adequate
ipsilateral GSV is absent, the use of autogenous vein
appears to consistently achieve the highest patency
and limb-salvage rates in most vascular surgery cen-
ters. In this report, the use of arm vein as the first
alternative for lower-extremity revascularization has
resulted in long-term patency and limb-salvage rates
that meet or exceed those reported for other alter-
native conduits, while preserving the contralateral
GSV for subsequent use. Finally, these patency and
limb-salvage rates were achieved without a signifi-
cant increase in morbidity or mortality in a patient
population with extensive comorbid conditions.
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Dr Keith D. Calligaro (Philadelphia, Pa). I would like
to congratulate Dr Faries and his associates at the Beth
Israel Deaconess Medical Center for presenting a landmark
paper reporting the results of 520 lower-extremity bypass
grafting procedures with arm vein in an 8-year period. This
experience represents an average of more than one leg
bypass graft with an arm vein per week. Their 1.2% 30-day
mortality and 3% early graft thrombosis rates are quite
remarkable in such a high-risk diabetic patient population.
In our admittedly much smaller experience comparing
arm vein and prosthetic bypass grafting procedures to
infrapopliteal arteries, which we reported to this Society 2
years ago, we also concluded that the extra time and effort
required to perform arm vein grafts was worthwhile
because of favorable patency rates.
My first question is why was angioscopy used to
inspect fewer than half of your arm vein grafts? Your group
has championed the use of this technique in identifying
intrinsic arm vein lesions; and largely because of your
group’s recommendations, we use angioscopy routinely
when arm veins are harvested.
Second, when ipsilateral greater saphenous vein was
not available, you recommended using arm veins as your
next choice, because the contralateral greater saphenous
vein was used in approximately 25% of patients during the
next 2 years in your series. The results of our group and
others, and even your results, strongly suggest that single-
segment greater saphenous veins have superior patency
rates to arm veins, especially when arm veins need to be
spliced together. To maybe change your strategy, why not
use the greater saphenous vein as your next choice, and, if
that leg gets into trouble, then use arm veins?
Third, in 13% of your bypass grafting procedures you
used arm veins for above-knee popliteal bypasses, instead
of prosthetic grafts. It would be interesting to poll the
audience to see how many would take the extra time and
effort to use an arm vein for a femoropopliteal above-knee
bypass graft. Quite frankly, we would probably use a pros-
thetic graft in those instances, unless the runoff was very
poor or there were other circumstances.
I greatly enjoyed your paper and commend your out-
standing results. Thank you.
Dr Peter L. Faries. Thank you, Dr Calligaro for your
questions.
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With regard to angioscopy, we used it in nearly all cases
early on in the experience and have used it with decreasing
frequency as our experience has accumulated. It is not used
currently in arm vein segments that are short or are con-
sidered to be widely patent and are going to be used in
reverse configuration. In a number of short segments, valve
lysis can be done with direct visualization as well.
As far as the use of the contralateral greater saphenous
vein is concerned, I think it is dependent on the specific
patient population that is being monitored at one’s individ-
ual vascular center. Our patient population has a number of
the comorbid factors that have been implicated in increasing
the likelihood that the contralateral greater saphenous vein
will be used for contralateral lower-extremity revasculariza-
tion. Most predominantly is diabetes mellitus, which was
present in 88% of our patients. But additional factors, such as
coronary artery disease, which was present in 77% of our
patients, also contribute to the need for revascularization of
the contralateral limb. This was demonstrated well by the
group at Dartmouth in their analysis of risk for contralateral
revascularization. Because of the high likelihood of con-
tralateral revascularization, we would tend to favor preserv-
ing the greater saphenous vein to give the revascularization
on the contralateral side the optimal chance for success.
Arm vein grafts in the femoral to above-knee popliteal
configuration comprise a relatively small percentage of the
bypass grafting procedures that were performed. The deci-
sion to use a prosthetic graft conduit or arm vein grafts in
that situation is based on the surgeon’s preference. Certainly,
there are some surgeons who would prefer to use a pros-
thetic graft for above-knee popliteal bypass grafting, as is the
case occasionally at our medical center.
Dr George Andros (Encino, Calif). I think that’s a
wonderful series of patients. You’ve obviously got the
habit now, and it’s pretty hard to break, because once you
get used to using autogenous vein, arm veins are very
attractive. I have some questions for you.
We have continued to accumulate our series, although
we haven’t reported lately, and now we have more than
1000 arm veins that we’ve placed in the last 30 years. The
series that Dr Whittemore presented in 1982 and our own
series showed that when you do arm vein bypass grafting
procedures for revisions, they tend not to perform as well,
in contrast to your series in which many of your patients
had redo operations and had the same results. Do you
think you could explain that?
You lumped composite grafts together. I’m not sure if
by composites you mean upper arm U loops or if you
mean composites in which you cut a piece out and then
sew the segments together. I think those are two different
kinds of composites, and I’d like your comment.
Our experience has been that when you have a com-
posite graft you have approximately a 2- to 3-times greater
chance of needing some sort of revision to the graft. Would
you comment?
I would like to make one important caveat for the use
of arm veins. We recently submitted an abstract dealing with
aneurysmal degeneration of arm vein bypass grafts and
saphenous vein bypass grafts. We found this to be a unique
complication in patients with popliteal aneurysm. Now here
are your patients who have diabetes mellitus with occlusive
disease, but I caution against the use of these conduits when
you’re treating popliteal aneurysms.
Thank you.
Dr Faries. Thank you, Dr Andros. We are well aware of
your pioneering work in the use of arm veins. We did see a
slight increasing trend toward improved patency for arm
veins that were used as the initial procedure, compared with
those used for revision or redo procedures. This trend did
not reach statistical significance with log-rank analysis; how-
ever, log-rank analysis is a very stringent statistical criterion.
As more experience is accumulated, that difference may
achieve statistical significance.
In our case, composite veins were considered to be
those in which two distinct arm vein segments were used
and sewn together with venovenostomy. Somewhat surpris-
ingly, we did not find a difference whether multiple arm
vein segments or single arm vein segments were used. And
this, we think, is because venovenostomy was rarely the site
of failure in the multiple-segment veins.
Dr Gary M. Gross (Huntsville, Ala). Your presenta-
tion included the overall patency for femoropopliteal
grafts, but not according to distal anastomotic site. I
would like to know specifically the patency of the arm
vein grafts to the popliteal artery above the knee.
Because polytetrafluoroethylene grafts are commonly
used to that level with reasonable results, how does your
arm vein patency at that level compare with the reported
prosthetic patency?
Second, basilic and cephalic vein are increasingly being
used for percutaneous central vein catheterization, which
may render these veins unsuitable as conduits. Have you
noticed more problems with that recently? Have you made
or should we make any special effort for medical and radi-
ologic colleagues to preserve the arm veins in potential
candidates for vascular bypass grafting? For example, we
try to avoid basilic peripherally inserted central catheter
lines in patients with diabetes mellitus, because the basilic
transposition makes a long-lasting arteriovenous fistula for
hemodialysis.
Dr Faries. In answer to the second question, no spe-
cial institutional policy is in place regarding the use of
peripherally inserted central venous catheters. However,
when we are planning to use arm vein for a bypass graft,
we reserve that arm and do not allow intravenous lines or
phlebotomy to be performed on it. The above-knee grafts
had primary and secondary patency rates greater than
90% at 1 year and 83% at 3 years. We are satisfied with
those patency rates in the above-knee anatomic configu-
ration. Thank you.
